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Background: Disease-specific patient-reported outcome measures (PROMs) have been developed as important
research tools in the study of various diseases. For hypothyroidism there exist three validated disease-specific
questionnaires in English: the Thyroid-Dependent Quality of Life Questionnaire (ThyDQoL), the Underactive Thyroid
Symptom Rating Questionnaire (ThySRQ) and the Thyroid Treatment Satisfaction Questionnaire (ThyTSQ). We report
psychometric properties of new German versions of the questionnaires including construct validity from two
independent samples.
Methods: 230 envelopes with ThyDQoL, ThySRQ and ThyTSQ were given out to patients receiving levothyroxine
for diagnosed hypothyroidism. Reliability and factor analyses were performed, correlations and hypothesised
subgroup differences calculated to assess psychometric properties. Independently, 18 patients with treated
hypothyroidism for autoimmune thyroiditis (Hashimoto’s disease) and 18 healthy control subjects were enrolled in a
clinical study. Participants filled in the above questionnaires alongside well-known generic PROMs, e.g. the Beck
Depression Inventory, the 12-item Well-Being Questionnaire and the Short-Form-36. Two blood samples were taken.
Groups were compared and correlations between disease-specific and generic instruments analysed. Relationships
between PROMs and biochemically determined thyroid hormone status were investigated.
Results: 102 patients returned completed questionnaires (response rate 44%). The newly translated questionnaires
had satisfactory psychometric properties. Cronbach’s alpha was 0.92 for ThyDQoL, 0.81 for ThySRQ and 0.86 for
ThyTSQ. For each of the questionnaires, a single factor structure explained the data best. Adequately treated
patients with thyroid stimulating hormone levels in the upper normal range reported more symptoms in the
ThySRQ. Those with autoimmune hypothyroidism reported being more bothered by depressive symptoms. Within
the clinical sample, correlation with well-known generic instruments revealed good construct validity. In the clinical
sample patients reported more symptoms in the ThySRQ, being more bothered by tiredness, higher depression and
reduced well-being despite biochemically adequate treatment. Correlations between PROMs and biochemical
thyroid hormone status revealed moderate though consistent associations.
Conclusions: Psychometric properties including construct validity of German versions of the ThyDQoL, ThySRQ and
ThyTSQ are satisfactory. Feasibility and sensitivity in a clinical sample could be shown. We encourage the use of
disease-specific PROMs in future studies as important additions to generic instruments in clinical research on
hypothyroidism.
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Hintergrund: Krankheitsspezifische Selbsteinschätzungsfragebögen, so genannte „patient-reported outcome
measures“(PROMs), wurden als wichtige Forschungsinstrumente für verschiedene Erkrankungen entwickelt. Für die
Hypothyreose wurden drei englischsprachige Fragebögen entwickelt: der Lebensqualitätfragebogen zur
Schilddrüsenunterfunktion (ThyDQoL), der Symptomfragebogen zur Schilddrüsenunterfunktion (ThySRQ) sowie ein
Fragebogen zur Behandlungszufriedenheit bei Schilddrüsenunterfunktion (ThyTSQ). Wir stellen psychometrische
Eigenschaften der neuen deutschen Versionen dieser Fragebögen vor, inklusive Daten zur Konstruktvalidität aus
zwei unabhängigen Stichproben.
Methoden: 230 Umschläge mit ThyDQoL, ThySRQ und ThyTSQ wurden an Patienten ausgegeben, die wegen einer
gesicherten Hypothyreose mit Levothyroxin substituiert wurden. Mit Hilfe von Reliabilitäts- und Faktoranalysen,
Korrelationsanalysen und hypothesengeleiteten Subgruppenvergleichen wurden die psychometrischen
Eigenschaften der Fragebögen analysiert. 18 Patienten mit behandelter Hypothyreose autoimmuner Genese
(Hashimoto Thyreoiditis) sowie 18 gesunde Kontrollprobanden nahmen an einer unabhängigen klinischen Studie
teil. Die Teilnehmer füllten zu den oben genannten auch bekannte generische PROMs aus, darunter das Beck
Depressions Inventar, den 12-Item Well-Being Questionnaire und den Short Form-36. Zwei Blutproben wurden
entnommen. Die Gruppen wurden verglichen und Korrelationen zwischen krankheitsspezifischen und generischen
Instrumenten sowie Zusammenhänge zwischen Fragebogendaten und Laborwerten berechnet.
Ergebnisse: 102 Patienten schickten ausgefüllte Fragebögen an die Autoren zurück (Rücklaufquote 44%). Die neu
übersetzten Fragebögen zeigten gute psychometrische Eigenschaften. Cronbach’s Alpha betrug 0.92 für den
ThyDQoL, 0.81 für den ThySRQ und 0.86 für den ThyTSQ. Alle Fragebögen wurden am besten durch eine
Einfaktorenlösung beschrieben. Patienten mit Thyroidea-stimulierendem Hormon (TSH) im oberen Normbereich
berichteten mehr Symptome im ThySRQ und diejenigen mit autoimmuner Genese stärkere Beeinträchtigung durch
depressive Symptome. Die Konstruktvalidität der Fragebögen konnte durch erwartungskonforme Korrelationen zu
generischen Fragebögen in der klinischen Studie nachgewiesen werden. Die Patientengruppe berichtete trotz
normwertigem TSH mehr Symptome im ThySRQ, mehr Beeinträchtigung durch Müdigkeit, sowie höhere
Depressionswerte und geringeres Wohlbefinden als die gesunde Kontrollgruppe. Wir konnten moderate aber
konsistente Zusammenhänge zwischen den Fragebogendaten und den Laborwerten finden.
Schlussfolgerung: Die psychometrischen Eigenschaften der Fragebögen ThyDQol, ThySRQ und ThyTSQ sowie ihre
Konstruktvalidität sind zufriedenstellend. Machbarkeit und Sensitivität der Fragebögen in einer klinischen Studie
konnten gezeigt werden. Die krankheitsspezifischen PROMs stellen eine wichtige Ergänzung zu den generischen
Instrumenten dar, mit potentiellem Nutzen für die zukünftige klinische Forschung auf dem Gebiet der
Hypothyreose.Background
Hypothyroidism or subclinical hypothyroidism affects 4
to 21% of the female population and 3 to 16% of the
male population [1]. Standard treatment for the highly
prevalent condition is replacement of thyroid hormone
by levothyroxine, artificial free thyroxine (fT4) [2]. The
definition of the targeted normal range of thyroid
hormone level is, however, still under debate [3-5].
Moreover, it has been reported that among patients
receiving this treatment, well-being is reduced even if
euthyroidism is reestablished [6,7].
It is still an open issue where patients’ reports of un-
wanted symptoms result from [8]. Explanations discussed
are independent effects of thyroid autoimmunity, the
most common cause of hypothyroidism [9-11], insufficient
normalisation of thyroid hormone levels at target tissues
such as the brain despite normal serum hormone levels
[12], selection bias in seeking health care [13] or reactiveprocesses to the awareness of having a chronic disease
[14]. Disentangling these possible causes has important
implications for treatment targets in this large patient
group. Crucial for successfully addressing the above issue
is the use of appropriate instruments to measure patient-
reported outcomes. It is important to differentiate between
perceived health status, psychological well-being and
quality of life as well as between generic and disease-
specific instruments [15,16]. All are valid and important
constructs to address patient-reported outcomes but
should be carefully distinguished to avoid misleading
interpretation of results. Symptom load has for example
often been interpreted as quality of life although perceived
symptoms may or may not influence quality of life in an
individual [15,16]. Health status is often confusingly
referred to as health-related quality of life [17]. It has been
shown for several clinical conditions such as peripheral
arterial disease or heart failure that disease-specific
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However, most studies still use exclusively generic
questionnaires and often self-constructed symptom lists
to assess patient-reported outcomes in hypothyroidism,
so reducing sensitivity to subtle effects and comparability
across studies [20-23].
The first hypothyroidism-specific instruments have
been developed and validated in recent years including
the Thyroid-Dependent Quality of Life Questionnaire
(ThyDQoL) [24,25]. The ThyDQoL measures the impact of
hypothyroidism on quality of life in general and in selected
domains tailored to the disease and to individual realities
by including importance ratings for each domain. The
Underactive Thyroid Symptom Rating Questionnaire
(ThySRQ) is in contrast a measure of hypothyroidism-
related symptoms and symptom bother [25]. Finally, the
Thyroid Treatment Satisfaction Questionnaire (ThyTSQ)
measures disease-specific treatment satisfaction [24,26]. It
is designed to cover hypothyroidism-specific aspects such
as satisfaction with current medication and dose.
All three hypothyroidism-specific questionnaires have
been developed and validated in English and use of the
questionnaires in any other language needs validation in
an independent sample to examine psychometric validity.
Although necessary, this is a demanding and time
consuming procedure, possibly contributing to the
paucity of validated translations. However, despite
known advantages over the use of exclusively generic or
non-validated instruments, the original questionnaires are
also relatively new, which may account for the fact that
they are not yet in widespread use. None of the validated
hypothyroidism-specific questionnaires available has been
evaluated for German so far, although interest in the field
is high in German speaking countries [10,21-23,27].
We are thus introducing the first three hypothyroidism-
specific PROMs in German to improve the array of
tools available for future research. We provide detailed
psychometric data including internal consistency and factor
structure of the questionnaires, as well as hypothesised
subgroup analyses. According to the literature we expect
more negative reports in patients with thyroid stimulating
hormone (TSH) in the upper normal range [28] and more
negative reports in patients with hypothyroidism of
autoimmune origin [10,27].
In addition, we have used the questionnaires in a
clinical study including 18 adequately treated patients
with hypothyroidism due to autoimmune thyroiditis
(Hashimoto’s disease) and 18 healthy control subjects.
The study also included a number of well-known generic
PROMs. Thereby, we were able to investigate construct
validity of the new questionnaires and feasibility in a
clinical context. We expect disease-specific and generic
instruments to be moderately correlated because similar,
though distinct, constructs are targeted. The clinical studyincluded assessment of TSH, fT4, free triiodothyronine
(fT3) as well as thyroid peroxidase antibodies (TPOAb)
and thyroglobulin antibodies (TgAb). This design allowed
investigation of the relationship between PROMs and
biochemical thyroid hormone status.
Methods
Linguistic validation
Linguistic validation was performed for ThyDQoL, ThySRQ
and ThyTSQ as previously described for similar instru-
ments [29]. English originals were translated into German
by two native German speakers, including a clinical endo-
crinologist (SK) and reconciled into a preliminary forward
translation by a psychologist (EQ). The resulting forward
translation was subsequently translated back into English
by each of two native English speakers. Any discrepancies
between original and back-translation were discussed
with the developer’s team and improvements made where
necessary. The resulting draft translation was then used
for cognitive debriefing interviews with five patients with
hypothyroidism of different origins, recruited from the
volunteer database of the Max Planck Institute for Human
Cognitive and Brain Sciences (MPI) and reimbursed for
their time. Example items of the final German versions can
be found in Figure 1.
Scoring of questionnaires
The scoring for the newly translated questionnaires
ThyDQoL, ThySRQ and ThyTSQ will be briefly
summarised as explained in detail elsewhere [25,26].
The ThyDQoL starts with two overview items on present
quality of life (present QoL) and impact of hypothyroidism
on quality of life in general (impact on QoL). The first
ranges from excellent (3) to extremely bad (−3), the second
from very much better (-3) to worse (1) without
hypothyroidism. The 18-item main questionnaire asks for
impact of hypothyroidism on various domains of life such
as work life or sex life (see [25] for a complete list of do-
mains). Nine of the domains have a “not applicable” option
to guarantee individual relevance of the items. For each
domain, if applicable, respondents rate whether life in
this domain would be very much better (−3) to worse
(1) without hypothyroidism. In addition, respondents
rate the importance of the respective domain from
very important (3) to not at all important (0). A
weighted domain impact score is calculated by multi-
plying both ratings for each domain resulting in scores
ranging from –9 (maximal negative impact of
hypothyroidism on quality of life) to 3 (maximal positive
impact of hypothyroidism). These scores can be summed
into an Average Weighted Impact Score (AWI–18, ranging
from –9 to 3) by summing all domain weighted impact
scores and dividing the result by the number of ap-
plicable and completed domains if at least half of
Figure 1 Sample items from the newly translated German versions of the (A) Thyroid-Dependent Quality of Life Questionnaire
(ThyDQoL), (B) the Underactive Thyroid Symptom Rating Questionnaire (ThySRQ), and (C) the Thyroid Treatment Satisfaction
Questionnaire (ThyTSQ).
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the AWI–14 can be calculated by excluding four
items which overlap with the ThySRQ. Finally, a free
comments section at the end allows respondents to indicate
further domains not covered in the questionnaire.
The 15-item ThySRQ requires a yes/no response on
whether each of the given hypothyroidism-related
symptoms such as feeling cold or weight gain has been
experienced in recent weeks (see [25] for a complete
list of symptoms). If experienced, the amount of bother
from the symptom is rated from not at all bothered (0)
to very much bothered (3). If a symptom is not experi-
enced bother rating for this item is zero.
The 7-item ThyTSQ covers several aspects of current
treatment satisfaction, e.g. general satisfaction with or con-
venience of treatment (see [24] for a complete list of items).
Items range from very satisfied (6) to very dissatisfied (0) or
equivalent. Range of the summed score is 0–42. The
ThyTSQ also offers a free comment section at the end.Patients and procedures
For the validation study 230 envelopes with questionnaires
were given out by local endocrinologists and the outpatient
department of the Clinic for Endocrinology at University
Hospital Leipzig. The questionnaires were accompanied
by a motivating letter and a questionnaire on basic
sociodemographic and disease details as shown in Table 1.
In the clinical study 25 patients with treated
hypothyroidism due to autoimmune thyroiditis inde-
pendent of the validation sample as well as 27 healthy
control subjects were enrolled after written informed
consent. Patients were recruited via internet advertisement,
local endocrinologists and the MPI’s volunteer database.
Healthy control subjects were recruited via the database
alone. The database consists of volunteers recruited via the
MPI’s website or via advertisement for former non-clinical
studies. All participants were reimbursed for their time.
The research protocol of both studies was approved by
the ethics committee of the University of Leipzig and
Table 1 Characteristics of the sample for psychometric validation
Sample characteristics Mean SD Range N
Age (years) 43.5 16.3 19-75 101
Sex (female/male) 93/8 101
Marital Status Single/Married/Divorced/Widowed 101
37/48/12/4
TSH (mU/l) 2.20 3.95 0.02-35.0 90
Treatment duration (years) 7.48 6.94 0.2 - 39.0 96
Current dose LT4* (μg/day) 97.9 42.4 0-250 99
Cause of hypothyroidism Autoimmune thyroiditis 75
Thyroidectomy for cold nodules or nodular goiter 13
Ablative treatment for hyperthyroidism 7
Lithium treatment 1
Thyroidectomy – cause not specified 2
Missing 3
*two participants additionally received 7.5/10 μg T3 respectively **comorbid conditions with potential influence occurring in more than one participant:
depression (4), migraine (4), diabetes (4), asthma (3), heart disease (2), polycystic ovary syndrome (2) and pregnancy (2); several patients had multiple comorbid
conditions. None of the non-reported rare comorbidities was a psychiatric illness. Abbreviaton: SD – Standard Deviation.
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of Helsinki.
Patients in the clinical study filled in the three newly
translated questionnaires ThySRQ, ThyDQoL and ThyTSQ
alongside well-known and validated generic instruments of
mood and well-being as part of a larger study. Healthy
control subjects completed the same questionnaires
except for the ThyTSQ and most parts of the ThyDQoL
because they are not meaningful to healthy subjects. The
ThyTSQ explicitly asks questions about the satisfaction
with the treatment that healthy subjects do not receive and
the ThyDQoL asks for the quality of life in several domains
in the style “If I did not have underactive thyroid, my
working life would be…”. However, the first question of
the ThyDQoL asks for general quality of life and is thus
meaningfully answerable for healthy control subjects. The
ThySRQ asks for symptoms independent of the disease, e.g.
“Have you felt tired in recent weeks?” which is also
meaningful to healthy control subjects. Please note
however that the use of any of the Thy questionnaires
in a healthy population has not been validated yet and
our study can thus only provide preliminary results.
General perceived physical and mental health status
was measured by the Short Form-36 (SF-36, [30]).
Higher values in the range of 0–100 in the two subscales
physical and mental health stand for better perceived
health. General mental strain was assessed by the Symptom
Check List (SCL-90-R, [31]), higher values in the range
of 0–4 meaning higher strain. General well-being was
measured with the 12-item Well-Being Questionnaire
(WBQ-12, [32]), higher values in the range of 0–36 indicate
better well-being. Generic instruments were given first
to prevent their interpretation being influenced by thecontent of the disease-specific instruments. Depression
was assessed by a questionnaire, the Beck Depression
Inventory (BDI, [33]) and a structured interview, the
Hamilton Depression Scale (HDS, [34]), in both instru-
ments higher values mean greater amounts of depression.
Cut-off scores for clinical depression are eleven points for
the BDI and seven points for the HDS.
Basic sociodemographic data were asked for in written
form. In addition, fasting blood samples were taken in the
morning to assess TSH, fT3, fT4, TPOAb and TgAb. Blood
samples were analysed at the Institute for Laboratory
Medicine of the University Hospital Leipzig by the fully au-
tomated Roche cobas system (Roche, Basel, Switzerland).
Statistical analysis
All questionnaire items entering psychometric evaluation
were checked for normal distribution by investigating
histograms and skewness scores. Normality as checked
by histograms and Kolmogorov-Smirnov tests for normal
distribution was not given for most variables. The skewness
threshold of ±2.58 [26] was slightly exceeded by two
items (ThyDQoL item getting out −3.2, ThySRQ item
appetite 3.9). Reflect and log transformation did not
significantly reduce skewness in these variables (getting out
2.7, appetite 3.7), so that statistics were calculated on the
original data, but nonparametric tests were chosen for
statistical analyses. Spearman’s rho and Mann–Whitney
U-tests (MW-U-tests) were chosen for correlations and
group comparisons respectively and parametric tests
were employed for exploratory analyses only when no
comparable nonparametric test was available, such as
partial correlation or analysis of covariance (ANCOVA).
Chi-square tests were used for comparison of nominal
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analyses and Bonferroni correction for multiple testing
was applied where necessary.
Results
Sample evaluation study
102 questionnaires were returned anonymously in stamped
addressed envelopes to the first author between September
2011 and November 2012; the response rate was 44%. Due
to the anonymous design of the study no data were
available on the non-responders. One participant reported
not being treated yet and was thus excluded from any
analysis. Among those reporting TSH values, 68 were
within the normal range of 0.4-4.0 mU/l ([35], see Table 1).
Seventy-one participants reported no or only symptom-free
comorbid conditions such as hypertension. Thirty reported
comorbidities likely to influence results (see Table 1)
and subgroup comparisons were controlled for these
influencing comorbidities.
Psychometric evaluation of the newly translated
instruments
As numbers for not applicable options were high in the
ThyDQoL (0% for family to 45% for depression) they
were coded as zero for factor and reliability analyses but
as not applicable for calculation of the AWI-18 and
AWI-14. One participant did not fill in the ThyDQoL, for
all others the AWI-18 and AWI-14 could be calculated.
Completion rate in the remaining sample was between
95 and 100% per item. Genuinely missing items were
excluded for factor and reliability analysis, leaving 79
complete datasets for analysis. Unforced factor analysis
on the 18 weighted-impact scores produced 4 factors,
but the Varimax rotated factor loadings did not allow a
meaningful interpretation. The screeplot suggested a
single most important factor explaining 45% of the
variance. A forced one-factor solution revealed that all
variables loaded saliently (above 0.30) on the single
factor, ranging from 0.36 (weight) to 0.82 (friendship
and physical ability) and all but the weight item even
above 0.40, implying robust findings [25]. Cronbach's
alpha was 0.92, and all variables had an acceptable
corrected item-total correlation above 0.20, ranging from
0.35 (weight) to 0.78 (physical ability). Thirty respondents
used the free comments section. Eleven mentioned
comorbidities not included in the present questionnaire.
Six of forty-nine, or 12% of women of childbearing age
(18–40 years) mentioned involuntary infertility. Fertility
may thus be a potentially relevant domain for inclusion in
future versions of the ThyDQoL at least when targeting
younger women.
98 complete datasets were available for factor and
reliability analysis of the ThySRQ. Two participants
missed one item each and one participant missed thefinal page (four items). Unforced factor analysis on
the symptom bother ratings revealed five factors.
However, the factors could not be interpreted in a
meaningful way and the screeplot pointed towards a
single factor solution. The forced 1-factor solution
explained 28% of the variance and variables loaded
between 0.20 (constipation) and 0.74 (concentration).
Only constipation loaded below 0.30 and nails (0.36)
below 0.40 on the single factor. Cronbach's alpha was
0.81. All variables except for constipation (0.13) had a
corrected item-total correlation above 0.20 ranging
from 0.28 (nails) to 0.63 (concentration).
99 complete datasets were available for factor and
reliability analysis of the ThyTSQ. One participant
missed a single item and one the whole questionnaire.
Unforced factor analysis produced a single factor as also
suggested by the screeplot. This factor explained 57% of the
variance. All variables loaded robustly (above 0.40) on this
factor, ranging from 0.48 (convenience) to 0.89 (how well
working). Cronbach's alpha was 0.86. All variables had a
corrected item-total correlation above 0.20, ranging from
0.37 (convenience) to 0.80 (how well working). Twenty-one
participants used the free comments section, but did so
only to stress points already covered by the ThyTSQ.
Descriptive results and comparison to the English originals
The current sample (n = 101) was significantly younger
than the original sample (mean = 44 vs. 55 years, one-
sample t-test p < 0.001; all comparison data from [25])
but comparable in the distribution of comorbidities. The
present sample mean of the AWI-18 (n = 100) was −1.50
(SD = 1.4, range −5.7 to 0), indicating negative impact of
hypothyroidism on quality of life. People reported signifi-
cantly less impact on quality of life than in the original sam-
ple (mean = −3.11; p < 0.001). General quality of life was
rated as “good” (n = 100, mean = 0.91, SD = 0.95, range −2
to +3) not significantly different from the original sample
mean = 0.89 (p > 0.1) and general impact of hypothyroidism
on quality of life was rated as “a little better without
hypothyroidism” (n = 98, mean = −0.88, SD = 0.76, range −3
to 0 vs. mean = −1.25; p < 0.001), less negative than in the
original sample. Mean number of reported symptoms was
5.6 (n = 98, SD = 3.3, range 0–13), which is significantly less
than in the original sample (mean = 7.4; p < 0.001). Sample
mean of the TSQ sum score was 31.6 (n = 99, SD = 7.6,
range 10–42), comparable to the reference finding [25]
(mean = 32.5; p > 0.1).
Intercorrelations
Correlations were performed between the three new
questionnaires to investigate construct validity. For better
comparability between correlations, data were excluded
listwise, resulting in n = 91 complete datasets entered into
all analyses reported in Table 2.











AWI-18 ——— 0.97* 0.51* 0.75* 0.57*
AWI-14 ——— ——— 0.52* 0.72* 0.56*
Present QoL ——— ——— ——— 0.30* 0.48*
Impact on QoL ——— ——— ——— ——— 0.55*
ThySRQ symptom bother ratings
Tiredness −0.39** −0.39** −0.28** −0.34** −0.37**
Weight gain −0.38** −0.33** −0.14 n.s. −0.34** −0.27*
Cold −0.23* −0.20 n.s. −0.27* −0.14 n.s. −0.07 n.s.
Constipation −0.13 n.s. −0.09 n.s. −0.08 n.s. −0.18 n.s. −0.16 n.s.
Hair −0.29* −0.32** −0.27* −0.24* −0.26*
Skin −0.35** −0.35** −0.26* −0.31** −0.26*
Nails −0.31** −0.31** −0.23* −0.34** −0.21 n.s.
Appetite −0.25* −0.23* −0.19 n.s. −0.11 n.s. −0.02 n.s.
Hearing −0.14 n.s. −0.12 n.s. −0.08 n.s. −0.13 n.s. 0.03 n.s.
Voice −0.32** −0.30* −0.30** −0.05 n.s. −0.21*
Speech −0.37** −0.35** −0.22* −0.25* −0.13 n.s.
Memory −0.22* −0.20 n.s. −0.22* −0.20 n.s. −0.06 n.s.
Concentration −0.42** −0.43** −0.47** −0.26* −0.43**
Giddy −0.33** −0.32** −0.23* −0.31** −0.22*
Depressed −0.48** −0.46** −0.56** −0.27* −0.45**
*p < 0.05, **p < 0.0033 corrected for multiple testing within ThySRQ symptom bother ratings. Abbreviations: ThyDQoL – Thyroid-Dependent Quality of Life
Questionnaire, ThySRQ – Underactive Thyroid Symptom Rating Questionnaire, ThyTSQ – Thyroid Treatment Satisfaction Questionnaire, AWI – Average Weighted
Impact Score, QoL – Quality of Life.
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to the ThySRQ items, so that spurious intercorrelations by
overlapping items between AWI-18 and ThySRQ can be
ruled out and the original AWI-18 will be used for all
further analyses. The single-item impact on QoL is highly
correlated with the multiple-item AWI-18, so that we will
use only the AWI-18 for further analyses. Correlations
between both AWI scores and ThySRQ symptom bother
ratings ranged between −0.09 and −0.48 all in the expected
direction but of small to moderate size, implying that
symptom bother and impact on quality of life are related
but distinct constructs. Treatment satisfaction as measured
by the ThyTSQ showed low to moderate mainly negative
correlations with the ThySRQ symptom bother ratings
(range 0.03 to −0.45) and moderate positive correlations
(range 0.48 to 0.57) with the different ThyDQoL indices.
Treatment satisfaction is thus meaningfully related to but
separable from the other two disease-specific PROMs.
Forward models of multiple regression analysis revealed
that among those ThySRQ items correlating significantly
with present QoL, depression (F(1,97) = 42.5, p < 0.001)
and feeling cold (F(2,96) = 25.1, p < 0.001) significantly
predicted present QoL, explaining 34% of the variance. The
impact of hypothyroidism on quality of life (AWI-18) wassignificantly predicted by depression (F(1,97) = 33.9), speech
problems (F(2,96) = 33.4), nail problems (F(3,95) = 27.0)
and tiredness (F(4,94) = 22.3), explaining 49% of the vari-
ance, all p < 0.001. Analogously, depression (F(1,96) = 24.2)
and tiredness (F(2,95) = 15.7) significantly predicted
treatment satisfaction, explaining 25% of the variance,
all p < 0.001. The ThySRQ depression item alone explained
31% of the variance of present QoL, 26% of variance of the
impact of hypothyroidism on QoL and 20% of the variance
of treatment satisfaction.
Subgroup analyses
Subgroup analyses were performed with pairwise dele-
tion of missing items in order to reduce information loss
for the smaller sample sizes considered here. Within the
group of adequately treated patients (n = 68) symptom
bother ratings of depression (r = 0.47, p < 0.001) and hair
(r = 0.37, p < 0.002) correlated significantly with TSH,
depression even after Bonferroni correction (p < .0033).
Additionally, age correlated negatively with TSH (r = −0.39,
p < .002). Therefore, an exploratory partial correlation
controlling for age was performed yielding the exact same
pattern as above, depression (r = 0.44, p < 0.001) and hair
(r = 0.42, p < 0.001) bother ratings correlating significantly
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obtained when considering either the full sample with
available TSH values (n = 91) or only adequately treated
patients with autoimmune thyroiditis (n = 51). Again
depression was the only correlation surviving Bonferroni
correction (r = 0.32, p < 0.002) in the full sample or
just missing Bonferroni correction in the group with
autoimmune thyroiditis (r = 0.37, p < 0.009).
Comparing adequately treated patients split by median
TSH (n = 34 in both groups, TSH median = 1.44 mU/l)
revealed that patients in the lower range were older
(49 vs. 40 years; p < 0.05) but groups did not differ in
the amount of comorbidities (p > 0.1), explicitly depression
(n = 2 in each group) nor gender (p > 0.1) or type of
diagnosis (autoimmune vs. other p = 0.1). Those in the
upper TSH range reported significantly more bother by hair
(1.3 vs. 0.5; p < 0.006), depression (1.4 vs. 0.6; p < 0.003) and
concentration (1.2 vs. 0.7; p < 0.05) symptoms and overall
more symptoms in the ThySRQ (6.4 vs. 4.8; p < 0.05).
Exploratory ANCOVAs controlling for age revealed
that only hair (p < 0.007) and depression symptom
bother (p < 0.005) differed significantly between TSH
groups independently of age. After Bonferroni correction,
only depression symptom bother was significant before
controlling for age.
Among the adequately treated participants with known
cause of hypothyroidism those with autoimmune thyroiditis
(n = 51) were compared to those reporting a different
diagnosis (n = 16). Groups did not differ in gender and
comorbidities, explicitly not in depression (n = 2 in each
group), but in TSH (autoimmune 1.63 mU/l vs. other
1.05 mU/l; p < 0.01) and age (40.9 vs. 57.3 years; p < 0.001).
The group with autoimmune thyroiditis reported sig-
nificantly higher bother ratings for depression (1.22 vs.
0.33; p < 0.009) as well as reduced treatment satisfaction
(30.7 vs. 35.4; p < 0.05) before Bonferroni correction
(corrected p < .0033). In an exploratory ANCOVA with age
and TSH as covariates the group effect on depression
remained significant on an uncorrected level.
Clinical sample
Two of the original 25 treated patients did not complete
the study for reasons unrelated to disease status. Five of the
remaining 23 treated patients had to be discarded because
of unstable doses or persistently heightened TSH levels.
Autoimmunity was either proven by positive TPOAb and/
or TgAb or hypoechogenicity at thyroid ultrasound from
clinical records. Nine of the originally 27 healthy control
subjects had to be discarded for either positive TPOAb,
TgAb or heightened TSH levels in two consecutive blood
samples taken about 3 months apart, leaving 18 participants
in both groups, see Table 3.
Correlations between the newly translated hypothyroidism-
specific questionnaires and previously validated andpublished questionnaires on mood and well-being
revealed that all correlated in the expected direction
although only a subset reached significance, see Table 4.
Correlations are between small and moderate.
Comparison of clinical groups
ThyDQoL and ThyTSQ are only meaningful to treated
patients as explained above. In a clinical study including a
control group only the ThySRQ and the ThyDQoL present
QoL item are thus meaningful for group comparisons,
although their use in a healthy sample still needs independ-
ent evaluation and reported results here are of preliminary
nature. Comparison of the two groups in the clinical study
revealed several significant results or statistical trends, see
Table 5. Among the ThySRQ symptom bother ratings only
tiredness (p < 0.003) reached significance after Bonferroni
correction. Results for the other ThySRQ symptoms are
not shown.
Correlation with thyroid parameters
Higher fT4 in the group of treated patients was correlated
significantly with lower impact of hypothyroidism on
quality of life as measured by AWI-18 (r = 0.51) before
Bonferroni correction. None of the other thyroid parame-
ters correlated significantly with the questionnaire data.
However, in an exploratory inspection of the full correlation
table, the majority of correlations were in the expected
direction of more negative reports with worse thyroid
status for TSH, fT4 and TPOAb and between the generic
instruments and TgAb, see Table 6. Interestingly, for the
disease-specific questionnaires, this pattern was completely
reversed for fT3 and TgAb.
Discussion
Validity of the newly translated questionnaires
All three questionnaires reached psychometric validity
comparable to the English originals and most import-
antly, mostly reached the standards as laid out in [25]
(factor loadings on single factor >0.4, Cronbach’s
Alpha >0.8, Corrected item-total correlations >0.2). The
ThySRQ only slightly missed the robustly salient factor
loading for the items constipation and nail problems as
similarly reported for the original ThySRQ [25] and the
weight gain item from the ThyDQoL missed the robust 0.4
loading, but still loaded saliently. The current sample was
on average 10 years younger than the original sample and
reported slightly better status on ThyDQoL and ThySRQ,
but similar treatment satisfaction in the ThyTSQ. However,
the current sample still reported a negative impact of
hypothyroidism and an average of six symptoms despite
biochemically adequate treatment, which is in line with
previous literature reporting residual complaints [6,7].
Treatment satisfaction was in the moderately positive
range but with room for improvement.
Table 3 Characteristics of the clinical sample with treated hypothyroidism in proven autoimmune thyroid disease and
the healthy control group
Sample characteristics Treated patient group n = 18 Healthy control group n = 18 p-value
Mean SD Range Mean SD Range
Age (years) 32.2 9.60 [18–54] 32.1 8.90 [18–53] >0.1
Sex (female/male) 16/2 16/2 >0.1
TSH (mU/l)* 1.96 1.42 [0.2 - 5.3] 2.63 0.95 [0.9 - 5.0] <0.05
fT3 (pmol/l)* 4.28 0.62 [3.2 - 5.6] 4.72 0.83 [3.2 - 6.3] =0.07
fT4 (pmol/l)* 18.2 1.61 [14–21] 15.6 2.24 [14–23] <0.001
TPOAb (U/ml)* 140 132 [9–457] 10.2 2.14 [7–14] <0.001
TgAb (U/ml)* 313 604 [5–2424] 17.3 7.47 [5–36] <0.001
Treatment duration (years) 4.41 4.21 [1–15] not applicable
Current dose (μg/day) 96.5 29.6 [50–150]
*laboratory values of initial blood sample, reference range was 0.4-4.0 for Thyroid Stimulating Hormone (TSH), 3.1-6.79 for free Triiodothyronine (fT3), 12.8-20.4 for
free Thyroxine (fT4), < 34 for Thyroid Peroxidase Antibodies (TPOAb) and < 33 for Thyroglobulin Antibodies (TgAb) [4,35]. Patients with slightly altered laboratory
values that spontaneously recovered to the normal range in a second blood sample taken 3–6 months later were considered as thyroid healthy or adequately
treated and included into the analysis. Abbreviaton: SD – Standard Deviation.
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allowed maximal data privacy and reduced bias due to
social desirability effects, no data were available on the
non-responders. However, our sample is comparable to
similar questionnaire studies on PROMs in treated
hypothyroidism, which include data on non-responders
according to age, sex ratio, cause of hypothyroidism,
percentage normal TSH levels, and disease duration.
Moreover, comparison of responders to non-responders
in these similar studies revealed only a slight bias with
respect to age and sex ratio [6,25,26]. Furthermore, our
sample showed a broad range and variance of disease
parameters (see Table 1) and reported severity of im-
pairment so that it is unlikely that the responders form
a highly selective group within the population of treated
patients with hypothyroidism.
Intercorrelation of ThySRQ items with ThyDQoL
replicated previous findings [25] again showing the
AWI-18 can be used together with the ThySRQ without
causing spurious correlations by four shared items. We
here additionally included the ThyTSQ and found
comparable effect sizes of correlations to ThySRQ itemsTable 4 Spearman correlations between hypothyroidism-spec
treated patients
Specific vs. generic instruments ThyDQoL present QoL ThyD
Short Form-36 physical 0.40
Short Form-36 mental 0.29
WBQ-12 0.53*
SCL-90-R −0.48*
Hamilton Depression Scale −0.53*
Beck Depression Inventory −0.56*
*p < 0.05, **p < 0.002 Bonferroni corrected. Abbreviations: WBQ – Well-Being Questi
Life Questionnaire, ThySRQ – Underactive Thyroid Symptom Rating Questionnaire, T
Weighted Impact Score, QoL – Quality of Life.and AWI-18 as already shown between the other two
questionnaires, implying that the three questionnaires
measure related but sufficiently separate constructs.
Among the ThySRQ items, it was depression that
explained most variance to predict present quality of life,
impact of hypothyroidism on quality of life and treatment
satisfaction, so depressive symptoms should be given
special attention when evaluating patient reports.
Higher depression bother rating was robustly associ-
ated with higher TSH across adequately treated patients
or the whole sample. Interestingly, although no further
results reached significance, the large majority of corre-
lations above 0.20 were in the direction of lower normal
TSH values with better patient-reported outcomes. Our
results are in line with the literature proposing to treat
patients towards TSH levels in the lower normal range
[5,28]. However, treatment outcomes other than patient
reports have to be considered, such as effects on heart
function or cognition [8,36], especially in patients beyond
the age of 75 [37], in order to achieve optimal treatment for
the individual patient. Patients reporting autoimmune thy-
roid disease as opposed to other causes for hypothyroidismific and generic patient-reported outcome measures in







onnaire, SCL – Symptom Check List, ThyDQoL – Thyroid-Dependent Quality of
hyTSQ – Thyroid Treatment Satisfaction Questionnaire, AWI – Average
Table 5 Patient-reported outcome measures in patients











Mean SD Mean SD
ThySRQ symptom number* 5.44 2.83 2.93 2.63 <0.05
ThyDQoL Present QoL 1.17 0.92 1.61 0.78 n.s.
Hamilton Depression Scale 6.00 3.76 3.72 2.35 =0.06
Beck Depression Inventory* 5.67 4.65 3.00 3.55 <0.05
Short Form-36 physical 54.80 8.50 56.07 5.07 n.s.
Short Form-36 mental 42.93 11.14 49.28 6.81 =0.09
WBQ-12 23.72 5.36 27.78 4.44 <0.05
SCL-90-R 0.39 0.28 0.35 0.33 n.s.
ThySRQ tiredness* 1.67 0.91 0.60 0.63 <0.0033
*Only available in n = 15 healthy control subjects, excluding the same subjects
for all analyses does not change any of the results. Abbreviations: SD –
Standard Deviation, WBQ – Well-Being Questionnaire, SCL – Symptom Check
List, ThyDQoL – Thyroid-Dependent Quality of Life Questionnaire, ThySRQ –
Underactive Thyroid Symptom Rating Questionnaire, QoL – Quality of Life.
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in line with claims of an independent role for autoimmunity
in residual symptoms [9-11].
Clinical study
Correlations between hypothyroidism-related questionnaires
and generic instruments in the clinical sample were all inTable 6 Spearman correlations between laboratory values




TSH fT3 fT4 TPOAb TgAb
ThyDQoL AWI-18 −0.231 −0.042 0.511** −0.191 0.072
ThyDQoL Present QoLresent
QoL
−0.231 −0.282 0.301 −0.011 0.192
ThySRQ number symptoms 0.261 0.092 −0.311 0.151 −0.212
ThyTSQ −0.171 −0.392 0.391 −0.021 0.052
Short Form-36 physical −0.371 −0.072 0.211 −0.331 −0.041
Short Form-36 mental 0.162 −0.212 −0.082 0.272 0.202
SCL-90-R 0.051 0.022 −0.231 0.241 0.241
WBQ-12 −0.151 0.051 0.361 −0.121 −0.031
Hamilton Depression
Scale Scale
0.191 0.102 −0.401 0.431 0.271
Beck Depression Inventory −0.122 −0.161 −0.401 0.061 0.161
*p < 0.05, 1in the expected direction, 2against the expected direction.
Abbreviations: WBQ – Well-Being Questionnaire, SCL – Symptom Check List,
ThyDQoL – Thyroid-Dependent Quality of Life Questionnaire, ThySRQ –
Underactive Thyroid Symptom Rating Questionnaire, ThyTSQ – Thyroid
Treatment Satisfaction Questionnaire, AWI – Average Weighted Impact Score,
QoL – Quality of Life, TSH – Thyroid Stimulating Hormone, fT3 – free
Triiodothyronine, fT4 – free Thyroxine, TPOAb – Thyroid Peroxidase Antibodies,
TgAb – Thyroglobulin Antibodies.the expected direction. The effect size was small to
moderate, meaning that the new disease-specific ques-
tionnaires do share common variance with the generic
instruments but also hold distinct variance to the more
generic instruments. They are thus valid additions for
future studies. Those disease-specific questionnaires
applicable also to healthy control subjects (ThySRQ
and the present QoL item of ThyDQoL) proved to be
as sensitive in detecting subtle differences in small clinical
samples as the well-established generic instruments. It is
remarkable that descriptively all results were in the
expected direction of more negative patient reports in the
treated patient group adding to the literature on residual
symptoms despite biochemically adequate treatment [6,7].
Only a few correlations between hormone levels and
patient-reported outcomes in treated patients reached
significance, possibly due to the low power of the study.
However, TSH, fT4 and TPOAb consistently correlated
in the expected direction of more negative PROMs with
worse biochemical status, and being most pronounced in
the disease-specific questionnaires. This, though necessarily
preliminary, favours a subtle relationship between certain
biochemical thyroid hormone markers within the normal
range and PROMs in treated patients. In contrast, fT3 and
TgAb showed a reverse (fT3) or inconsistent (TgAb)
relationship to PROMs, in line with clinical routine
that does not consider them as valid markers of thyroid
hormonal status. Interestingly, TPOAb were equally
related to patient-reported outcomes as TSH and fT4.
This is in line with literature considering autoimmunity as
an independent factor for treatment outcome [10,27].
We acknowledge the small sample size of the clinical
study. However, our sample size is comparable to other
clinical studies [23] in the field and it is thus important
to show that instruments are also sensitive enough to
detect group differences in small samples as shown here.
Among the Thy questionnaires, we found significant
group differences for the number of reported symptoms
in the ThySRQ and for the tiredness item, but not for
the overall quality of life question in the ThyDQoL.
These results should be interpreted with caution as the
use of the questionnaires in healthy control subjects has
not been validated so far, but are still of preliminary
interest to encourage further validation and use of the
questionnaires in cross-sectional studies including healthy
control subjects. Our clinical sample was of a young age
range in order to exclude effects of aging and comorbidities
on the data, and thus does not contribute to research on
possible specificities of hypothyroidism in the elderly such
as beneficial effects on the coronary system in patients over
85 years, which leads to reduced mortality [37]. Therefore,
treatment targets a slightly higher TSH value in the very
elderly. Studies on quality of life and perceived symptoms
in this age group are not known to us and would be
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greatly resemble those of general aging and therefore are
prone to confusion in elderly subjects [37]. Our findings
therefore cannot be extended to the very elderly. Most
importantly however, the 10-year age difference and stron-
ger severity of reported symptoms between our evaluation
sample and the original one [25] did not influence the find-
ings on the psychometric properties of the questionnaires,
so that our main finding, the sufficient psychometric quality
of the questionnaires can be generalised to the use in young
and middle aged cohorts.
Finally, the majority of participants were female, owing
to the gender bias in the prevalence of the disease, as a
consequence of which our results can only be generalised
reliably to the female population and the study included
only patients already on treatment for hypothyroidism, so
that the interpretation is confined to the group of already
treated patients.
Conclusions
The three hypothyroidism-specific PROMs ThyDQoL,
ThySRQ and ThyTSQ, introduced here as new German
translations, show good psychometric properties and
meaningful relations to TSH. In a small clinical sample
we have found preliminary evidence for construct valid-
ity with well-established generic instruments and for a
relationship to thyroid laboratory measures. We thus
recommend them for use in clinical studies and encourage
further linguistic validation into other languages to improve
available research tools as a prerequisite for progress in
clinical research on hypothyroidism.
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